Corindus’ CorPath GRX cleared for both PCI, peripheral vascular intervention

Already approved for robot-assisted PCI, Corindus Vascular Robotics’ CorPath GRX System is now cleared by the FDA for peripheral vascular interventions (PVIs). The system is the first to receive FDA clearance for both procedures.

According to Corindus, peripheral artery disease (PAD) affects an estimated 8.5 million people in the United States.

"My colleagues and I have seen first-hand how CorPath GRX can overcome the challenges of manual PCI and I am excited to apply the capabilities of robotics to effectively treat PAD patients," said Alan Lumsden, MD, chief of the department of cardiovascular surgery at Houston Methodist Hospital. "As a training site for future robotic interventionalists, I look forward to teaching these techniques to further enhance the quality of care for patients with both CAD and PAD."

Corindus is interested in exploring whether its technology can facilitate procedures performed by operators in remote locations, in addition to robot-assisted procedures. In January, the company announced it was partnering with Mayo Clinic to test the feasibility of “telestenting,” which could ultimately provide more access to PCI for rural and underserved populations.